Neurocrine Biosciences (NBIX) Misses Q4 Earnings Expectations

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on February 11, 2026 that fell short of analyst expectations.

The Healthcare company reported earnings per share of $1.88, missing the consensus estimate of $2.09 by $0.21 per share. Revenue came in at $805.5M, beating the estimate of $786.7M.

Neurocrine Biosciences's stock moved following the earnings release. The stock currently trades at $126.07 with a market capitalization of $15.4B.